The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
New Data Establish Long-Term Efficacy for 2 Modern Modalities in NSCLC and Melanoma
For nearly a decade, immunotherapy and molecularly targeted agents have been the focus of intense development. Now emerging evidence suggests that both modalities can deliver long-term benefits for patients, but the findings may prompt additional questions of how best to fit these transformative therapies into treatment landscapes.
Merkel Cell Carcinoma Study Matches TMB With Disease Drivers
The molecular profile of Merkel cell carcinoma differs depending upon whether the malignancy is driven by ultraviolet light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings.
EU Panel Recommends 4-Week Nivolumab Dosing Schedule in Adjuvant Melanoma
September 24th 2019The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.
Dr. Nathan on Long-Term Outcomes With Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
September 19th 2019Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the long-term outcomes with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.
Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma
September 11th 2019Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitoripilimumab and the PD-1 inhibitor nivolumab, in melanoma.
Dr. Polsky on Validating ctDNA as a Biomarker in BRAF-Mutant Melanoma
September 10th 2019David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the next steps that have to be taken to validate the clinical utility of circulating tumor DNA (ctDNA) as a biomarker in BRAF-mutant melanoma.
An Instinct for Innovation Drives Robert's Melanoma Research
September 7th 2019A 2018 Giants of Cancer Care® award winner in Melanoma and Other Skin Cancers, Caroline Robert, MD, PhD, has helped clarify the role of immune therapies in advanced melanoma with her groundbreaking work on clinical trials evaluating anti– CTLA-4 and anti–PD-1 antibodies.
Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain Metastases
September 6th 2019Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib plus trametinib.
Encorafenib/Binimetinib Combo Continues to Show Survival Benefit in BRAF-Mutant Melanoma
Encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival and progression-free survival compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.
Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCC
August 29th 2019Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.
Dr. Long on the Results of the Pooled Analysis of the COMBI-i Trial in Melanoma
August 28th 2019Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses the results of the pooled analysis of parts 1 and 2 of the phase III COMBI-i study.
Dr. Geiger on Challenges of Patients With CSCC Enrolled in KEYNOTE-630 Trial
August 27th 2019Jessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma.
Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma
August 22nd 2019Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses data from a phase I trial exploring the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma.
Checkpoint Inhibitors Vault Into Frontline Settings Across Tumor Types
August 6th 2019By the end of 2018, the 57 oncology drugs launched from 2014 to 2018 had gained 89 indications across 23 cancer types. These new agents included numerous checkpoint inhibitors, which saw tremendous uptake based on their ability to dramatically improve patient outcomes.
FDA Grants Bempegaldesleukin Plus Nivolumab Breakthrough Designation in Melanoma
August 1st 2019The FDA granted a breakthrough therapy designation to the combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Dr. Flaherty on the Rationale to Explore Triplet Therapy in BRAF V600E-Mutant Melanoma
August 1st 2019Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy and director of clinical research, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses the rationale to explore triplet therapy in BRAF V600-mutant melanoma.
Dr. Nathan on 5-Year Survival Outcomes of COMBI-d and COMBI-v Trials in BRAF V600-Mutant Melanoma
August 1st 2019Paul D. Nathan, MBBS, PhD, FRCP, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib plus trametinib in patients with BRAF V600–mutant unresectable or metastatic melanoma.